Clinical trial registry record

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 1, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04685590
Last registry update
April 1, 2026
Status
Active Not Recruiting
Phase
Phase 2
Sponsor
Washington University School of Medicine
Enrollment
48
Countries
United States, Spain
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
48
Population
ALL · 60 Years
Duration
2021-12-22 to 2029-01-01
Intervention
Dasatinib + Quercetin; Placebo Capsules
Comparator
Placebo
Outcomes measured
Serious Adverse Events (SAEs) and Adverse Events (AEs) in treatment group as compared to placebo group — Baseline to We…; Change in cellular senescence blood marker Senescence-Associated Secretory Phenotype (SASP) composite score — Baseline…; Change in cellular senescence blood marker Cluster of Differentiation 3 (CD3) in blood — Baseline to Week 12; Change in cellular senescence blood marker cyclin-dependent kinase inhibitor 2A (p16INK4A+) in blood — Baseline to Week…; Change in cellular senescence blood marker T cells in blood — Baseline to Week 12; Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) slope — Baseline to Week 48; Change in the 14 - item Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14) slope — Baseline to Wee…; Change in Positron Emission Tomography (PET) - Computed Tomography (CT) - brain tau pathology — Baseline to Week 48
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Senolytics · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

senolytics
Read the original source →Export JSON